Skip to contentS
Spyre Therapeutics, Inc.
S
SYRESpyre Therapeutics, Inc. Q2 2026 · 10-Q
Revenue—
Net Income-$36.20M-$36.20MN/M vs Q2 2025 EPS, diluted—
Operating Income-$41,639,000N/M Operating Cash Flowderived-$69,877,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Aug 4, 2026 · 35 d after period end